NASDAQ:NVUS - Novus Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.16 +0.01 (+0.47 %) (As of 01/18/2019 04:00 PM ET)Previous Close$2.15Today's Range$2.16 - $2.3852-Week Range$1.52 - $8.61Volume7,400 shsAverage Volume8,615 shsMarket Capitalization$21.48 millionP/E Ratio-0.94Dividend YieldN/ABeta1.56 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. Receive NVUS News and Ratings via Email Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVUS Previous Symbol CUSIPN/A Webwww.northviewreit.com Phone949-238-8090Debt Debt-to-Equity RatioN/A Current Ratio10.69 Quick Ratio10.69Price-To-Earnings Trailing P/E Ratio-0.94 Forward P/E Ratio-1.49 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.79Profitability EPS (Most Recent Fiscal Year)($2.30) Net Income$-13,110,000.00 Net MarginsN/A Return on Equity-55.53% Return on Assets-51.74%Miscellaneous Employees7 Outstanding Shares9,422,000Market Cap$21.48 million OptionableNot Optionable Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions What is Novus Therapeutics' stock symbol? Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS." How were Novus Therapeutics' earnings last quarter? Novus Therapeutics Inc (NASDAQ:NVUS) issued its earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.01. View Novus Therapeutics' Earnings History. When is Novus Therapeutics' next earnings date? Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Novus Therapeutics. What price target have analysts set for NVUS? 2 analysts have issued 1-year price targets for Novus Therapeutics' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Novus Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 339.8% from the stock's current price. View Analyst Price Targets for Novus Therapeutics. What is the consensus analysts' recommendation for Novus Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics. Has Novus Therapeutics been receiving favorable news coverage? Press coverage about NVUS stock has been trending positive on Friday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novus Therapeutics earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. Who are some of Novus Therapeutics' key competitors? Some companies that are related to Novus Therapeutics include Tiziana Life Sciences (TLSA), Acasti Pharma (ACST), Ovid Therapeutics (OVID), Pharmaxis (PXSLY), Iterum Therapeutics (ITRM), Humanigen (HGEN), Correvio Pharma (CORV), Alpine Immune Sciences (ALPN), Provention Bio (PRVB), Infinity Pharmaceuticals (INFI), Tetraphase Pharmaceuticals (TTPH), CTI BioPharma (CTIC), Medicure (MCUJF), Elite Pharmaceuticals (ELTP) and Entasis Therapeutics (ETTX). Who are Novus Therapeutics' key executives? Novus Therapeutics' management team includes the folowing people: Mr. Gregory J. Flesher, CEO & Director (Age 48)Dr. Catherine C. Turkel, Pres (Age 57)Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 53) How do I buy shares of Novus Therapeutics? Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novus Therapeutics' stock price today? One share of NVUS stock can currently be purchased for approximately $2.16. How big of a company is Novus Therapeutics? Novus Therapeutics has a market capitalization of $21.48 million. The biopharmaceutical company earns $-13,110,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Novus Therapeutics employs 7 workers across the globe. What is Novus Therapeutics' official website? The official website for Novus Therapeutics is http://www.northviewreit.com. How can I contact Novus Therapeutics? Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected] MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 162 (Vote Outperform)Underperform Votes: 159 (Vote Underperform)Total Votes: 321MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: Can individual investors take part in an IPO?